

Recombinant antigens, monoclonal antibodies

March 2019—Binding Site's Immunologicals Group has added five recombinant Epstein-Barr virus antigens to its line of products for in vitro diagnostic manufacturing and research applications. The EBV capsid antigen P18; EBV capsid antigen P23; EBV early antigen P138; EBV early antigen P54; and EBV nuclear antigen EBNA1, P72 have been designed for use as components within solid phase enzyme immunoassay test procedures, especially ELISA. The antigens are *E. coli* source-derived recombinant proteins.

The company has also added purified monoclonal antibodies to be used for the analysis and testing of the hepatitis C virus and include HCV core-2 mAb, HCV core-12 mAb, HCV core-18 mAb, and HCV Ns3 (3.7.4.6) mAb. These monoclonal antibodies have been designed for use as components within enzyme immunoassay test procedures, including ELISA, and are sourced from mice and manufactured to a purity level of greater than 95 percent.

In a separate release, the company announced that it provides ethically sourced serum and plasma biological materials from a variety of infectious disease state conditions, including those with IgM and IgG antibodies to cytomegalovirus, Epstein-Barr virus, HSV 1, HSV 2, measles, mumps, rubella, syphilis, and toxoplasma. Materials can be supplied in milliliter formats or in bulk liter formats. Evaluation samples are also available for testing.

Binding Site, 800-633-4484